An additional study of AZD6738 investigates solid tumors (including pancreatic cancer) and determines response rates to therapy with ATR kinase inhibitor monotherapy and in combination with olaparib in an ATM loss and an ARID1A mutated subgroup (NCT03682289). Here, ARID1A is linked to familial pancreatic carcinoma.